PT - JOURNAL ARTICLE AU - Christina Bahrs AU - Aurelia Kimmig AU - Sebastian Weis AU - Juliane Ankert AU - Stefan Hagel AU - Jens Maschmann AU - Andreas Stallmach AU - Andrea Steiner AU - Michael Bauer AU - Wilhelm Behringer AU - Michael Baier AU - Miriam Kesselmeier AU - Cora Richert AU - Florian Zepf AU - Martin Walter AU - André Scherag AU - Michael Kiehntopf AU - Bettina Löffler AU - Mathias W. Pletz TI - Seroprevalence of SARS CoV-2 antibodies in healthcare workers and administration employees: a prospective surveillance study at a 1,400-bed university hospital in Germany AID - 10.1101/2020.09.29.20203737 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.29.20203737 4099 - http://medrxiv.org/content/early/2020/09/29/2020.09.29.20203737.short 4100 - http://medrxiv.org/content/early/2020/09/29/2020.09.29.20203737.full AB - Background Healthcare workers (HCWs) are at particular risk to acquire SARS-CoV-2 infections.Aim The objectives of this study were to compare SARS-CoV-2 IgG seroprevalence and compliance to wear personal protective equipment (PPE) between HCWs working within (high-risk) or outside (intermediate-risk) units treating suspected or confirmed COVID-19 patients. In addition, administration staff (low-risk) was included.Materials Co-HCW is a prospective cohort study among employees at the Jena University Hospital, Germany. Since 16th March 2020, 50 SARS-CoV-2 inpatients and 73 outpatients were treated in our hospital. Mandatory masking was implemented on 20th March 2020. We here evaluated seroprevalence using two IgG detecting immunoassays, assessed COVID-19 exposure, clinical symptoms and compliance to wear PPE.Findings Between 19th May and 19th June 2020 we analysed 660 employees [out of 3,228; 20.4%]. Eighteen participants (2.7%) had SARS-CoV-2 antibodies in at least one immunoassay. Among them, 13 (72.2%) were not aware of direct COVID-19 exposure and 9 (50.0%) did not report any clinical symptoms. We observed no evidence for an association between seroprevalence and risk area (high-risk: 2 of 137 HCWs (1.5%), intermediate-risk: 10 of 343 HCWs (2.9%), low-risk: 6 of 180 administration employees (3.3%); p=0.574). Reported compliance to wear PPE differed (p<0.001) between working in high-risk (98.3%) and in intermediate-risk areas (69.8%).Conclusion No evidence for higher seroprevalence against SARS-CoV-2 in HCWs working in high-risk COVID-19 areas could be observed, probably due to high compliance to wear PPE. Compared to administration employees, we observed no additional risk to acquire SARS-CoV-2 infections by patient care.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialGerman Clinical Trials Register (DRKS00022432)Funding StatementInternal funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The local ethics committee of the Friedrich-Schiller-University Jena (approval no. 2020-1774.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the authors upon reasonable request.